1. Neutralization of CSF1 and Ad5-HRG treatment.
Neutralization of CSF1 and Ad5-HRG treatment. A, Schematic of treatment strategy. Screws were implanted into the skull and one week later (day 1), 7,500 GL261 cells were inoculated into the caudate nucleus (n = 8–12 mice/group). Ad5 vectors were delivered at day 7 and 13, and the experiment ended 21 days after GL261 cell inoculation. Neutralizing αCSF1 antibody was delivered by intraperitoneal injection at day 2 (1 mg/mouse) and days 6, 10, and 14 (0.5 mg/mouse). B, GL261 tumor sizes at the experimental endpoint expressed as a percentage of buffer-treated tumors with each experimental arm. C, Quantification of CD45+ cells. D, Quantification of CD8a+ cells. Error bars, SEM. Statistical analyses were done using one-way ANOVA followed by Tukey post hoc test (C and D) or one-way ANOVA followed by Bonferroni post hoc and Student t test (B). *, P < ns, not significant.
Francis P. Roche et al. Mol Cancer Ther 2018;17:
©2018 by American Association for Cancer Research